Provectus Biopharmaceuticals, Inc. (PVCT) stock
PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
$0.05+0.00 (+0.39%)
Close on Oct 19, 2026Market cap $20.55MP/E –Yield –
Provectus Biopharmaceuticals shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Provectus Biopharmaceuticals's shares outstanding was 420M at Jun 30, 2026. For fiscal 2025 it was 420M, up 0.1% from the year before. Over ten years it grew 7.9% a year on average. The highest annual figure on record is 420M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 420M | +0.1% |
| FY2024 | Dec 31, 2024 | 420M | +0.1% |
| FY2023 | Dec 31, 2023 | 420M | +0.0% |
| FY2022 | Dec 31, 2022 | 419M | +2.8% |
| FY2021 | Dec 31, 2021 | 408M | +3.8% |
| FY2020 | Dec 31, 2020 | 393M | +1.7% |
| FY2019 | Dec 31, 2019 | 387M | +1.1% |
| FY2018 | Dec 31, 2018 | 382M | +3.5% |
| FY2017 | Dec 31, 2017 | 369M | +57.9% |
| FY2016 | Dec 31, 2016 | 234M | +19.5% |
| FY2015 | Dec 31, 2015 | 196M | +11.3% |
| FY2014 | Dec 31, 2014 | 176M | +33.2% |
| FY2013 | Dec 31, 2013 | 132M | +16.8% |
| FY2012 | Dec 31, 2012 | 113M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 420M | 0.0% |
| Q1 FY2026 | Mar 31, 2026 | 420M | 0.0% |
| Q4 FY2025 | Dec 31, 2025 | 420M | -0.0% |
| Q3 FY2025 | Sep 30, 2025 | 420M | +0.1% |
| Q2 FY2025 | Jun 30, 2025 | 420M | +0.2% |
| Q1 FY2025 | Mar 31, 2025 | 420M | +0.2% |
| Q4 FY2024 | Dec 31, 2024 | 420M | +0.2% |
| Q3 FY2024 | Sep 30, 2024 | 420M | +0.1% |
| Q2 FY2024 | Jun 30, 2024 | 420M | +0.0% |
| Q1 FY2024 | Mar 31, 2024 | 420M | +0.0% |
| Q4 FY2023 | Dec 31, 2023 | 420M | +0.0% |
| Q3 FY2023 | Sep 30, 2023 | 420M | +0.0% |
| Q2 FY2023 | Jun 30, 2023 | 419M | +0.0% |
| Q1 FY2023 | Mar 31, 2023 | 419M | +0.0% |
| Q4 FY2022 | Dec 31, 2022 | 419M | +0.6% |
| Q3 FY2022 | Sep 30, 2022 | 419M | +2.3% |
| Q2 FY2022 | Jun 30, 2022 | 419M | +3.9% |
| Q1 FY2022 | Mar 31, 2022 | 419M | +4.3% |
| Q4 FY2021 | Dec 31, 2021 | 417M | +6.2% |
| Q3 FY2021 | Sep 30, 2021 | 410M | +4.2% |
| Q2 FY2021 | Jun 30, 2021 | 404M | +3.3% |
| Q1 FY2021 | Mar 31, 2021 | 402M | +3.0% |
| Q4 FY2020 | Dec 31, 2020 | 393M | +0.9% |
| Q3 FY2020 | Sep 30, 2020 | 393M | +2.0% |
| Q2 FY2020 | Jun 30, 2020 | 391M | +1.5% |
| Q1 FY2020 | Mar 31, 2020 | 391M | +1.5% |
| Q4 FY2019 | Dec 31, 2019 | 389M | +0.5% |
| Q3 FY2019 | Sep 30, 2019 | 386M | +0.7% |
| Q2 FY2019 | Jun 30, 2019 | 385M | +0.8% |
| Q1 FY2019 | Mar 31, 2019 | 385M | +1.9% |
| Q4 FY2018 | Dec 31, 2018 | 387M | +4.4% |
| Q3 FY2018 | Sep 30, 2018 | 383M | +3.4% |
| Q2 FY2018 | Jun 30, 2018 | 382M | +3.0% |
| Q1 FY2018 | Mar 31, 2018 | 377M | +3.3% |
| Q4 FY2017 | Dec 31, 2017 | 371M | +26.2% |
| Q3 FY2017 | Sep 30, 2017 | 371M | +66.2% |
| Q2 FY2017 | Jun 30, 2017 | 370M | – |
| Q1 FY2017 | Mar 31, 2017 | 365M | – |
| Q4 FY2016 | Dec 31, 2016 | 294M | – |
| Q3 FY2016 | Sep 30, 2016 | 223M | – |
See a number that looks wrong?